Filter Results
:
(1,381)
Show Results For
-
All HBS Web
(3,343)
- Faculty Publications (1,381)
Show Results For
-
All HBS Web
(3,343)
- Faculty Publications (1,381)
Page 1 of
1,381
Results
→
- May 2, 2024
- Article
Require Hospitals to Disclose Their Pandemic Plans Now
By: Regina E. Herzlinger, Richard J. Boxer and Ben Creo
The COVID-19 pandemic demonstrated that U.S. hospital and health care systems were ill-prepared for the surge of patients who overwhelmed available health care resources. An overlooked resource deserves more attention: the availability of intensive care unit (ICU)...
View Details
Keywords:
COVID-19 Pandemic;
Crisis Management;
Knowledge Sharing;
Governance Compliance;
Planning;
Health Industry;
United States
Herzlinger, Regina E., Richard J. Boxer, and Ben Creo. "Require Hospitals to Disclose Their Pandemic Plans Now." Health Affairs Forefront (May 2, 2024).
- May 2024
- Article
True Costs of Uterine Artery Embolization: Time-Driven Activity-Based Costing in Interventional Radiology Over a 3-Year Period
By: Julia C. Bulman, Nicole H. Kim, Robert S. Kaplan, Sarah Schroeppel DeBacker, Olga R. Brook and Ammar Sarwar
The study used time-driven activity-based costing (TDABC) to estimate the costs to perform uterine artery embolization (UAE). Utilization times for patients undergoing outpatient UAE for fibroids or adenomyosis were captured from electronic health record timestamps and...
View Details
Bulman, Julia C., Nicole H. Kim, Robert S. Kaplan, Sarah Schroeppel DeBacker, Olga R. Brook, and Ammar Sarwar. "True Costs of Uterine Artery Embolization: Time-Driven Activity-Based Costing in Interventional Radiology Over a 3-Year Period." Journal of the American College of Radiology 21, no. 5 (May 2024): 721–728.
- April 2024
- Case
Dr. Tom Mihaljevic and Cleveland Clinic
By: Linda A. Hill and Lydia Begag
In December 2022, Dr. Tomislav (“Tom”) Mihaljevic, CEO and President of Cleveland Clinic, was reflecting on the last few years at the hospital, marked both by unprecedented challenges and remarkable achievements. Cleveland Clinic had recently been ranked the world’s...
View Details
Keywords:
Recruitment;
Retention;
Analytics and Data Science;
Digital Transformation;
Digital Platforms;
Innovation and Management;
Innovation Leadership;
Human Capital;
Leadership;
Leadership Development;
Leadership Style;
Leading Change;
Organizational Culture;
Organizational Structure;
Organizational Change and Adaptation;
Mission and Purpose;
Outcome or Result;
Performance;
Performance Evaluation;
Health Industry;
Cleveland;
London;
Abu Dhabi;
Florida;
Ohio
Hill, Linda A., and Lydia Begag. "Dr. Tom Mihaljevic and Cleveland Clinic." Harvard Business School Case 424-031, April 2024.
- April 2024
- Case
Unleashing Human Magic at Best Buy
By: Leonard A. Schlesinger, Sunil Gupta and Amram Migdal
The case examines the transformation of Best Buy under CEO Hubert Joly's leadership from 2012. Facing significant business challenges, including competition from online and physical retailers, Joly implemented the "Renew Blue" turnaround strategy, which focused on...
View Details
Keywords:
Change;
Change Management;
Transformation;
Transition;
Communication Intention and Meaning;
Communication Strategy;
Customer Focus and Relationships;
Customers;
Health;
Digital Transformation;
Digital Strategy;
Job Cuts and Outsourcing;
Labor;
Leadership;
Leadership Development;
Leadership Style;
Leading Change;
Management;
Management Practices and Processes;
Management Style;
Business or Company Management;
Crisis Management;
Mission and Purpose;
Organizational Change and Adaptation;
Organizational Culture;
Outcome or Result;
Failure;
Success;
Personal Development and Career;
Strategy;
Strategic Planning;
Adaptation;
Competition;
Retail Industry;
Minneapolis;
Minnesota;
United States
- April 2024
- Case
Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight Loss Drugs
By: Joseph L. Badaracco, Tom Quinn and John Schultz
Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in the 1920s had focused on producing insulin to treat diabetes. In 2017, however, it released Ozempic, a diabetes treatment with the revolutionary side effect of...
View Details
Keywords:
Cost vs Benefits;
Decisions;
Judgments;
Values and Beliefs;
Global Strategy;
Health Care and Treatment;
Patents;
Growth and Development Strategy;
Growth Management;
Product Positioning;
Supply and Industry;
Supply Chain;
Corporate Social Responsibility and Impact;
Mission and Purpose;
Philanthropy and Charitable Giving;
Opportunities;
Social Issues;
Equality and Inequality;
Pharmaceutical Industry;
Pharmaceutical Industry;
Denmark;
United States;
Europe;
China;
India;
Middle East;
North Africa
- April 2024
- Article
A Machine Learning Algorithm Predicting Risk of Dilating VUR among Infants with Hydronephrosis Using UTD Classification
By: Hsin-Hsiao Scott Wang, Michael Lingzhi Li, Dylan Cahill, John Panagides, Tanya Logvinenko, Jeanne Chow and Caleb Nelson
Backgrounds: Urinary Tract Dilation (UTD) classification has been designed to be a more objective grading system to evaluate antenatal and post-natal UTD. Due to unclear association between UTD classifications to specific anomalies such as vesico-ureteral reflux (VUR),...
View Details
Wang, Hsin-Hsiao Scott, Michael Lingzhi Li, Dylan Cahill, John Panagides, Tanya Logvinenko, Jeanne Chow, and Caleb Nelson. "A Machine Learning Algorithm Predicting Risk of Dilating VUR among Infants with Hydronephrosis Using UTD Classification." Journal of Pediatric Urology 20, no. 2 (April 2024): 271–278.
- March–April 2024
- Article
Retailers and Health Systems Can Improve Care Together
By: Robert S. Huckman, Vivian S. Lee and Bradley R Staats
Health systems are struggling to address the many shortcomings of health care delivery: rapidly growing costs, inconsistent quality, and inadequate and unequal access to primary and other types of care. However, if retailers and health systems were to form strong...
View Details
Keywords:
Health Care;
Retail;
Retailers;
Consumer;
Health Care and Treatment;
Value;
Consumer Behavior;
Business Model;
Partners and Partnerships;
Health Industry;
Health Industry;
United States
Huckman, Robert S., Vivian S. Lee, and Bradley R Staats. "Retailers and Health Systems Can Improve Care Together." Harvard Business Review 102, no. 2 (March–April 2024): 120–127.
- March 2024
- Article
Differences in Care Team Response to Patient Portal Messages by Patient Race and Ethnicity
By: Mitchell Tang, Rebecca Mishuris, Lily Payvandi and Ariel Dora Stern
Importance: The COVID-19 pandemic was associated with substantial growth in patient portal messaging. Higher message volumes have largely persisted, reflecting a new normal. Prior work has documented lower message use by patients who belong to minoritized racial...
View Details
Keywords:
Health Pandemics;
Technology Adoption;
Prejudice and Bias;
Equality and Inequality;
Communication Technology;
Race;
Ethnicity;
Health Industry
Tang, Mitchell, Rebecca Mishuris, Lily Payvandi, and Ariel Dora Stern. "Differences in Care Team Response to Patient Portal Messages by Patient Race and Ethnicity." JAMA Network Open 7, no. 3 (March 2024).
- March 2024
- Article
Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act
By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that...
View Details
Keywords:
Policy;
Government Legislation;
Health Care and Treatment;
Negotiation;
Price;
Pharmaceutical Industry
Vogel, Matthew, Pragya Kakani, Amitabh Chandra, and Rena M. Conti. "Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act." Nature Biotechnology 42, no. 3 (March 2024): 406–412.
- February 2024
- Teaching Note
AB InBev: Brewing Up Forecasts during COVID-19
By: Mark Egan and C. Fritz Foley
Teaching Note for HBS Case No. 224-020. In July 2021, the CEO of AB InBev's European operations and his team strategized to position the company for success post-pandemic. As the world's largest beer company, boasting over 500 brands, revenue of $46 billion, and a...
View Details
- February 2024
- Case
Best Buy Health: Enabling Care at Home
This case explores retailer Best Buy’s decision to enter health care. Best Buy Health aims to enable care at home across three prongs: consumer health, active aging, and virtual care. A key pillar of Best Buy Health's strategy is leveraging the Geek Squad—the company's...
View Details
- 2024
- Article
Beyond the 510(k): The Regulation of Novel Moderate-Risk Medical Devices, Intellectual Property Considerations, and Innovation Incentives in the FDA’s De Novo Pathway
By: Mateo Aboy, Cristina Crespo and Ariel Stern
Moderate-risk medical devices constitute 99% of those that have been regulated by the U.S. Food and Drug Administration (FDA) since it gained authority to regulate medical technology nearly five decades ago. This article presents an analysis of the interaction between...
View Details
Keywords:
Governing Rules, Regulations, and Reforms;
Health Care and Treatment;
Technology Adoption;
Technological Innovation;
Safety;
Medical Devices and Supplies Industry;
United States
Aboy, Mateo, Cristina Crespo, and Ariel Stern. "Beyond the 510(k): The Regulation of Novel Moderate-Risk Medical Devices, Intellectual Property Considerations, and Innovation Incentives in the FDA’s De Novo Pathway." Art. 29. npj Digital Medicine 7 (2024).
- February 2024
- Case
Compass Pathways: Pioneering Psychedelic Treatment
By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no...
View Details
Keywords:
Commercialization;
Corporate Strategy;
Competitive Strategy;
Product Launch;
Health Testing and Trials;
Research and Development;
Laws and Statutes;
Pharmaceutical Industry;
Europe;
United States;
United Kingdom
Zuzul, Tiona, Kisha Lashley, and Gamze Yucaoglu. "Compass Pathways: Pioneering Psychedelic Treatment." Harvard Business School Case 724-412, February 2024.
- February 2024
- Article
Representation and Extrapolation: Evidence from Clinical Trials
By: Marcella Alsan, Maya Durvasula, Harsh Gupta, Joshua Schwartzstein and Heidi L. Williams
This article examines the consequences and causes of low enrollment of Black patients in clinical
trials. We develop a simple model of similarity-based extrapolation that predicts that evidence is
more relevant for decision-making by physicians and patients when it...
View Details
Keywords:
Representation;
Racial Disparity;
Health Testing and Trials;
Race;
Equality and Inequality;
Innovation and Invention;
Pharmaceutical Industry
Alsan, Marcella, Maya Durvasula, Harsh Gupta, Joshua Schwartzstein, and Heidi L. Williams. "Representation and Extrapolation: Evidence from Clinical Trials." Quarterly Journal of Economics 139, no. 1 (February 2024): 575–635.
- January 2024
- Supplement
Buurtzorg
By: Ethan Bernstein and Tatiana Sandino
As co-founders of home nursing company Buurtzorg, Jos de Blok and Gonnie Kronenberg prized both self-management and organizational learning. Buurtzorg’s 10,000 nurses across 950 neighborhood nursing teams in the Netherlands were empowered to manage themselves, both in...
View Details
Keywords:
Organizational Design;
Management Style;
Business Model;
Knowledge Dissemination;
Learning;
Organizational Culture;
Health Industry;
Netherlands
Bernstein, Ethan, and Tatiana Sandino. "Buurtzorg." Harvard Business School Multimedia/Video Supplement 424-705, January 2024.
- January 2024 (Revised April 2024)
- Teaching Note
Somatus: Value-Based Kidney Care (A) & (B)
By: Ariel D. Stern, Robert S. Huckman and Sarah Mehta
This teaching note accompanies case no. 622-009 and 622-045 (Somatus: Value-Based Kidney Care, A and B).
View Details
- January 2024
- Background Note
Evaluating Innovations in the Organization of Primary Care: What Type of Innovation Is It and How Well Does It Align with the Six Factors?
By: Regina E. Herzlinger and James Wallace
How can we evaluate if innovative health care ventures can do good—benefit society—and do well—become financially viable? This question is the topic of the first module in the Innovating in Health Care course book.
This note and "Health Stop (A): What Type... View Details
This note and "Health Stop (A): What Type... View Details
- January 2024
- Case
Vibrant Health
By: Henry McGee and Sarah Mehta
This case is about nutritional supplements company Vibrant Health, among the 100 largest Black-owned businesses in the U.S. After acquiring the company from its white founder in 2007, co-owners Ted and Paige Parker significantly grew its sales. Set in September 2023,...
View Details
- January 2024
- Article
A Cost Model for a Low Threshold Clinic Treating Opioid Use Disorder
By: Sarah E. Wakeman, Elizabeth Powell, Syed Shehab, Grace Herman, Laura Kehoe and Robert S. Kaplan
The US fee-for-service payment system under-reimburses clinics offering access to comprehensive treatments for opioid use disorder (OUD). The funding shortfall limits a clinic’s ability to expand and improve access, especially for socially marginalized patients with...
View Details
Wakeman, Sarah E., Elizabeth Powell, Syed Shehab, Grace Herman, Laura Kehoe, and Robert S. Kaplan. "A Cost Model for a Low Threshold Clinic Treating Opioid Use Disorder." Journal of Behavioral Health Services & Research 51, no. 1 (January 2024): 22–30.
- January 2024
- Article
Cost of Exempting Sole Orphan Drugs from Medicare Negotiation
By: Matthew Vogel, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim and Benjamin N. Rome
Importance: The Inflation Reduction Act (IRA) requires Medicare to negotiate prices for some high-spending drugs but exempts drugs approved solely for the treatment of a single rare disease.
Objective: To estimate Medicare spending and global... View Details
Objective: To estimate Medicare spending and global... View Details
Vogel, Matthew, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim, and Benjamin N. Rome. "Cost of Exempting Sole Orphan Drugs from Medicare Negotiation." JAMA Internal Medicine 184, no. 1 (January 2024): 63–69.